ASCO GU 2017: The diverse genomic landscape of low-risk prostate cancer. - Poster Session Highlights
Orlando, Florida USA (UroToday.com) The use of genomic classifier has been adopted in the prognostication of prostate cancer patients on active surveillance. For instance, the Decipher score was developed using prostatectomy and biopsy specimens, and externally validated in a cohort of active surveillance patients. In this light, the investigators from UCSF used RNA sequencing data to classify active surveillance group into quartiles. As shown in the study, genomic heterogeneity was apparent in patients with equivalent clinical risk factors. The followup data on these patients are forthcoming and it would be very interesting to see whether the genomic subclassifcations of the homogeneous clinical risk groups truly separated out patients with different clinical courses.
Dr. Cooperberg points out the importance in formulating different active surveillance regimen according to the risk of patients’ genomic classification. Indeed, some patients will be identified as candidates for early aggressive therapy, while others may be fit for watchful waiting.